Novavax is exploring development of a Wuhan-coronavirus recombinant nanoparticle vaccine candidate, H.C. Wainwright analyst Vernon Bernardino tells investors in a research note. The company intends to develop a vaccine candidate from the genetic sequence of the coronavirus when it becomes available for research by the infectious disease community, which could be in the coming days, adds the analyst. He believes results from a vaccine lethal challenge study could be a positive catalyst later in Q1 for shares of Novavax. As such, Bernardino reiterates a Buy rating on Novavax with a $17 price target.